Working… Menu

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00704158
Recruitment Status : Completed
First Posted : June 24, 2008
Last Update Posted : February 19, 2015
Information provided by (Responsible Party):
Celldex Therapeutics ( CuraGen Corporation )

Brief Summary:
This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial to further evaluate the safety and efficacy of CR011-vcMMAE.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: CR011-vcMMAE Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer
Study Start Date : June 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Intervention Details:
  • Drug: CR011-vcMMAE
    administered as an intravenous infusion on Day 1 of a 21 day cycle.

Primary Outcome Measures :
  1. To evaluate the safety and tolerability of CR011-vcMMAE in breast cancer patients [ Time Frame: throughout the study ]
  2. To determine the MTD of CR011-vcMMAE in breast cancer patients [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. Evaluation of efficacy (progression-free survival rate at 12 weeks, objective response rate, time to response, duration of response and time to progression) [ Time Frame: throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Females with confirmed breast cancer
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
  • Locally advanced or metastatic disease who have received at least two prior chemotherapeutic regimens for breast cancer, as follows:

    • At least one regimen must have been for locally advanced or metastatic disease
    • Subject must have received an anthracycline, a taxane, and capecitabine in any combination unless the subject was intolerant to or not a candidate for any of these agents
    • Hormonal therapy, biologic therapy (such as trastuzumab or bevacizumab), or immunotherapy do not count as one of the 2 regimens
    • Subjects with HER2/neu overexpressing tumors must have been treated with trastuzumab except in situations where the subject was intolerant to or not a candidate for trastuzumab
  • Documented progressive disease within 6 months of the last regimen
  • Adequate bone marrow, renal and liver function
  • Signed informed consent

Main Exclusion Criteria:

  • Chemotherapy, radiation, hormonal therapy, or bevacizumab within two weeks, or trastuzumab or investigational therapy within three weeks before treatment start
  • Neuropathy > NCI-CTCAE Grade 1
  • Active brain metastases.
  • New York Heart Association class III or IV heart disease
  • Unstable angina
  • Uncontrolled arrhythmia
  • A marked baseline prolongation of QT/QTc interval
  • Pregnant or breast-feeding women, and women of childbearing age and potential who are not willing to use effective contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00704158

Layout table for location information
United States, Florida
Florida Cancer Specialists
Ft. Myers, Florida, United States, 33916
Hematology Oncology Associates
Lake Worth, Florida, United States, 33461
United States, Georgia
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
United States, New York
Cornell University
New York, New York, United States, 10065
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
CuraGen Corporation

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: CuraGen Corporation Identifier: NCT00704158     History of Changes
Other Study ID Numbers: CR011-CLN-20
First Posted: June 24, 2008    Key Record Dates
Last Update Posted: February 19, 2015
Last Verified: February 2015
Keywords provided by Celldex Therapeutics ( CuraGen Corporation ):
locally advanced breast cancer
metastatic breast cancer
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Glembatumumab vedotin
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs